Exelixis (EXEL) Free Cash Flow Growth (1y) (2011 - 2026)
Exelixis (EXEL) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 7.12% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 1,092.51% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 66.37% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 3.98% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Exelixis | 14.44 Bn | 13.66 Bn | 590.86 Mn | 20.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 20.07% |
| Jan 2, 2026 | 40.66% |
| Oct 3, 2025 | 9.77% |
| Jul 4, 2025 | -59.15% |
| Apr 4, 2025 | 252.58% |
| Jan 3, 2025 | 9,315.52% |
| Sep 27, 2024 | 143.66% |
| Jun 28, 2024 | -1.79% |
| Mar 29, 2024 | -18.31% |
| Dec 29, 2023 | -104.01% |
| Sep 29, 2023 | 2.82% |
| Jun 30, 2023 | 383.51% |
| Mar 31, 2023 | -49.06% |
| Dec 30, 2022 | 35.06% |
| Sep 30, 2022 | -6.17% |
| Jul 1, 2022 | -85.25% |
| Apr 1, 2022 | 446.85% |
| Dec 31, 2021 | 125.64% |
| Apr 2, 2021 | -51.07% |
| Apr 3, 2020 | -66.66% |